Reckitt Reorganizes To Develop Health Care, Emerging Markets
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.
You may also be interested in...
Schiff Supplements, MJN Formulas, Other Reckitt Benckiser Consumer Brands Get Their Own Home
UK manufacturer in January begins operating with a separate health care division, representing 60% of sales with products including Schiff supplements and Mead Johnson infant and adult formulas, and a home care/hygiene division led by Lysol disinfectants. The plan piques analysts' expectations that operating the divisions separately will lead to divesting one.
Reckitt Benckiser Gives Consumer Health Portfolio Its Own Home – What's Next?
UK manufacturer in January begins operating with a separate health care division, representing 60% of sales with products including Mucinex and Mead Johnson infant and adult formulas, and a home care/hygiene division led by Lysol disinfectants. The plan piques analysts' expectations that operating the divisions separately will lead to divesting one.
Reckitt Benckiser Gives Consumer Health Portfolio Its Own Home – What's Next?
UK manufacturer in January begins operating with a separate health care division, representing 60% of sales with products including Mucinex and Mead Johnson infant and adult formulas, and a home care/hygiene division led by Lysol disinfectants. The plan piques analysts' expectations that operating the divisions separately will lead to divesting one.